





Annual General Meeting of Shareholders

Telix Pharmaceuticals
ASX: TLX | NASDAQ: TLX
10.00am (Sydney time)
21 May 2025



Important information

This presentation should be read together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX) and the U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this presentation are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this presentation, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in this presentation.

This presentation may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Telix’s actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

This presentation also contains estimates and other statistical data made by independent parties and by Telix relating to market size and other data about its industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data and estimates. In addition, projections, assumptions and estimates of Telix’s future performance and the future performance of the markets in which it operates are necessarily subject to a high degree of uncertainty and risk.

Telix’s first generation PSMA-PET imaging product, gallium-68 (⁶⁸Ga) gozetotide injection (also known as ⁶⁸Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the U.S. Food and Drug Administration (FDA), by the Australian Therapeutic Goods Administration (TGA), by Health Canada, by the Brazilian Health Regulatory Agency (ANVISA), by the UK Medicines and Healthcare Products Regulatory Agency (MHRA), by the French National Agency for the Safety of Medicine and Health Products (ANSM) and in multiple countries within the European Economic Area (EEA) following a positive decentralized procedure (DCP) opinion by the German Federal Institute for Drugs and Medical Devices (BfArM). Gozellix® (kit for the preparation of gallium-68 (⁶⁸Ga) gozetotide injection) has been approved by the U.S. FDA.


Telix’s osteomyelitis (bone infection) imaging agent, technetium-99m (^{99m}Tc) besilesomab, marketed under the brand name Scintimun®, is approved in 32 European countries and Mexico. Telix’s miniaturized surgical gamma probe, SENSEI®, for minimally invasive and robotic-assisted surgery, is registered with the FDA for use in the U.S. and has attained a Conformité Européenne (CE) Mark for use in the European Economic Area. No other Telix product has received a marketing authorization in any jurisdiction.

Telix’s results are reported under International Financial Reporting Standards (IFRS). This presentation includes various non-IFRS financial information to reflect its underlying performance. These non-IFRS measures include Adjusted EBITDA. Non-IFRS measures have not been subject to audit or review. For further information on the reconciliation of non-IFRS financial information to Telix’s statutory measures, reasons for usefulness and calculation methodology, please refer to the Alternative performance measures section of Telix’s 2024 Annual Report.

This presentation has been authorized for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

©2025 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country. Pixclara and Zircaix brand names subject to final regulatory approval.





ersonal use only

Annual General Meeting of Shareholders

CEO's address

Dr. Christian Behrenbruch




Our mission is to be the global leader in radiopharmaceuticals

Telix is delivering to its growth strategy



Deliver

our late-stage
therapeutic pipeline



Build

the next generation of
radiopharmaceuticals



Grow

our industry-leading
precision medicine
business



Expand

our global
infrastructure for
product delivery

A diversified, vertically-integrated radiopharma business

Telix has built a foundation for sustainable growth



Expanding, global commercial portfolio

- Illuccix®, Gozellix® and Scintimun®: approved products
- Commercially active in 35 countries¹
- Illuccix® pathway towards marketing authorization established for Japan and China



Broad and deep theranostic pipeline


- ProstACT Global: Part 1 interim readout
- Glioblastoma and renal therapy: pivotal trials planned to initiate in 2025
- Next-generation assets advancing into the clinic



Global infrastructure to meet future demand


- Strengthen supply chain resilience and localized manufacturing
- Integration of RLS Radiopharmacies further diversifies revenue
- Recent acquisitions add specialist skills and capabilities

Revenue (US\$M)



+55%
Year on year
(YoY)

Adjusted EBITDA² (US\$M)



+76%
YoY




All figures in this presentation are recast in US\$ and provided on an unaudited basis.

1. Australia, Austria, Brazil, Bulgaria, Canada, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, UK, U.S.
2. Earnings before interest, tax, depreciation, amortization, U.S. listing costs, acquisition transaction costs and other gains/(losses) (net).

Capital allocation framework

Strategically reinvesting earnings to deliver value-creation opportunities



2025 focus: Global commercial expansion

Launch preparation for new markets and new products

U.S.



- Gozellix: follow-on PSMA product, approved March 2025



- Zircaix¹ BLA² filed with FDA December 2024
- Expanded access program at >30 sites globally



- Preparing to re-file U.S. NDA⁴
- Expanded access program active in the U.S.

International

- Illuccix®: UK and European country rollout from H1 2025
- Illuccix® China Phase 3 study completed

- Included in EAU³ guidelines as an emerging technology
- Engagement with EU regulator and manufacturers
- China bridging study commenced

- **Pixclara¹**: Targeted global regulatory filings, opportunities in select markets where access is currently restricted
- **Scintimun®**: Relaunch in current indication



1. Provisional brand name subject to final regulatory approval.
2. Biologics license application.

3. European Association of Urology Guidelines on Renal Cell Carcinoma (April 2024).
4. New drug application.

Telix PSMA multi-product strategy

Growing the U.S. market as leaders in PSMA imaging

Telix PSMA

- **Protect and grow market share:** Through customer experience and innovation
- **Expand patient reach, customer choice:** Differentiated as the only company with two approved PSMA imaging agents
- **Increase clinical utilization:** Label-expansion study commencing in 2025
- **Product development:** Pipeline of new products, delivering continued innovation in PSMA imaging

SHATTERING LIMITATIONS IN
PSMA

illuccix
(kit for the preparation of gallium Ga 68 gozetotide Injection)

Break free, and offer your patients the imaging they deserve.

- A highly accurate ⁶⁸Ga PSMA-PET agent
- An advanced tracer that expands the geographic distribution and utility of PSMA
- A fully reimbursable product


Gozellix
kit for the preparation of gallium Ga 68 gozetotide injection



Sample U.S. campaign for U.S. approved product, intended for U.S. healthcare professional audience only. Registrations vary country to country, always refer to local label and approval status. Gozellix is not currently approved in any country outside of the U.S.

Therapeutics: Core to our strategy

Momentum building across our pipeline of differentiated assets



Progress late-stage therapeutic pipeline

- Accelerate ProstACT GLOBAL pivotal trial of TLX591, first rADC¹ in 1L/2L mCRPC²
- Submit INDs to progress potential first-in-class radiotherapeutics to pivotal phase in other core areas
 - TLX250 in ccRCC⁴ and TLX101 in recurrent glioblastoma

Advance next-generation therapeutic programs

- Expand development in prostate cancer with ²²⁵Ac-TLX592 & TLX090 for bone pain in end-of-life setting
- Expand development in neuro-oncology with ²¹¹At-TLX102
- Explore multi-indication asset strategies leveraging validated pan-tumor targets, CAIX⁵ and FAP⁶

1. ClinicalTrials.gov ID: NCT06520345.
2. Radio antibody-drug conjugate.
3. Metastatic castrate resistant prostate cancer.
4. Clear cell renal cell carcinoma – most common form of kidney cancer.
5. Carbonic anhydrase IX.
6. Fibroblast Activated Protein


New clinical data reports promising efficacy data for TLX101

IPAX-Linz study substantiates patient benefit in high-grade glioma


- Phase 2, single-arm, investigator-initiated study, enrolled eight patients
- **Well tolerated**, no serious adverse events reported
- **Median overall survival** of 32.2 months from initial diagnosis and 12.4 months from initiation of treatment¹
- Adaptive dosing regime, TLX101 in combination with external beam radiation therapy (EBRT)
- Findings consistent with IPAX-1 study, in a more advanced and complex study cohort
- Telix's investigational imaging agent TLX101-CDx used as companion diagnostic in the study

Pivotal trial in recurrent setting planned for 2025:
Investigational New Drug (IND) filing planned for mid-year


Glioblastoma patient (salvage) with clinically stable disease 18 months from initiation of TLX101 therapy²




Baseline T = 0³




TLX101 #1 & #2⁴




T = 10 mos



TLX101 #3 & #4⁴



T = 16 mos



T = 18 mos

Patient representative scans - individual results may vary.



1. Telix ASX disclosure 16 April 2025. Data presented at NMN May 2025.
2. TLX101 Compassionate Use program. Case study presented at NMN symposium May 2025. Credit A. Braat, UMC Utrecht.

3. TLX101-CDx ([18F] FET) PET (positron emission tomography).
4. Overlay post therapy SPECT (single photon emission computed tomography).

Expanding global infrastructure


Localized production to service major global markets

Our strategy is to:

Build competitive advantage through resources and expertise

Scale to meet rapid growth and demand

Build partnerships to drive success



Case study: Lead generator

Recently acquired companies enable development and commercial pathway



Developed and validated a breakthrough generator technology for the production of lead-212 (^{212}Pb) and successfully completed first production

212Pb

Lead-212 generator

Alpha therapy

Telix Targeting Technology
(formerly ImaginAb)

Novel biologics development platform and clinically validated candidates with pharmacokinetic characteristics suited to Lead-212



To support future scale up through engineering and expertise

Distribution



U.S. footprint with capacity for lead generator installation to support future nationwide distribution

Case study: ARTMS

Scaling-up production to meet future demand



QUANTM Irradiation System® (QIS®)

Production technology for isotopes including ^{68}Ga , ^{89}Zr , ^{64}Cu , and $^{99\text{m}}\text{Tc}$: clean, large-scale, cost-efficient and translatable to all upcoming industry-based products



ARTMS' QIS enables:



Multi-Curie production of ^{68}Ga extending patient reach and driving radiopharmacy efficiencies



Centralized, large-scale, cost-effective production of Zr-89, for use with a biologic



Expanded distribution and enhanced production capacity for cyclotrons, to be installed through RLS and partner networks



Zircaix is a provisional brand name and subject to regulatory approval

Delivering the plan

Near-term catalysts



Deliver our late-stage therapeutic pipeline



Build the next generation of radiopharmaceuticals



Grow our industry-leading precision medicine business



Expand our global infrastructure for product delivery

2025



IPAX-Linz (TLX101) therapy study readout



ProstACT Global (TLX591) Ph 3 IND granted in China



ZOLAR (TLX300) patient dosing



Novel biologics platform and Tx assets transactions completion



Gozellix® approval (U.S.)



Illuccix® EEA¹, UK and Brazil approvals



Illuccix® China Ph 3 bridging study complete



RLS acquisition completion



TMS Brussels South GMP accreditation

ProstACT Global Ph 3 Part 1 complete

IPAX-2 (TLX101) therapy study complete

TLX250 program update

TLX592 alpha therapeutic trial commencement²

PSMA biopsy expansion study commencement²

TLX101, TLX250 pivotal trials commencement²

TLX252 alpha trial commencement²

ZOLAR trial Part A complete

Zircaix³ anticipated FDA approval decision (U.S.)

SubtlePET + Zircaix³ (combo) AI filing and approval decision (U.S.)

Gozellix filing (Aus)

Illuccix® Japan Ph 3 trial enrolment²



1. European Economic Area.
2. Subject to regulatory approval.
3. Brand name subject to final regulatory approval.

Contact:

Kyahn Williamson
SVP Investor Relations and Corporate
Communications

kyahn.williamson@telixpharma.com




Illustration showing TLX250 binding to carbonic anhydrase IX and internalization